Epilepsy Facts From the BIO Investor Forum

  • Epilepsy is a neurological disorder characterized by hyper-synchronous electrical discharge in the brain. The disease affects approximately 1% of the U.S. population (3 million) with a slightly higher 1-2% worldwide incidence due to less consistent prenatal care. The incidence is also expected to increase in the U.S. due to the aging population.
  • The current epilepsy drug market is more than $14B world wide. However, 90% of the sales result from non-epilepsy CNS indications including chronic pain. One notable exception is Kepra with over $1B in epilepsy indication sales due to a superior safety profile.
  • It is estimated that approximately 36% of epilepsy patients are pharmaco-resistant and medically refractive to currently available therapies. New epilepsy drugs with novel mechanisms of actions are needed to treat this large and growing patient population. In addition, over 50% of patients discontinue or are not compliant with current therapies due to epilepsy drug side effects.
  • In addition, only approximately 150 sales reps are required to detail products to neurologists who specialize in epilepsy disorders, making seizure disorders a potential high margin attractive market for biopharmaceutical companies.
Advertisements

One Response

  1. There is always some good investment opportunities available in the biotech/pharmaceutical markets.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: